47 results
424B5
IKT
Inhibikase Therapeutics Inc
22 May 24
Prospectus supplement for primary offering
8:55am
Stable Phase Chronic Myelogenous Leukemia, or SP-CML. A three-part dose finding/dose equivalence study in 66 healthy volunteers (known as ‘the 501 … indications include diseases with large patient populations, such as PD, as well as orphan indications, such as, Multiple System Atrophy and Chronic
8-K
EX-99.1
6aqo2k
7 Feb 24
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA
7:59am
424B5
ocki npr8n
1 Feb 24
Prospectus supplement for primary offering
4:49pm
8-K
EX-99.1
lwrm bhhhvoxvzhp8
20 Sep 23
Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity
11:23am
424B3
yyt5h5lntz
4 Apr 23
Prospectus supplement
4:57pm
POS AM
hx0idh 4nzqo
31 Mar 23
Prospectus update (post-effective amendment)
4:11pm
8-K
EX-99.1
pycdgu 5jrgl8rbw5
17 Nov 22
Inhibikase Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity
4:30pm
8-K
EX-99.1
hi50aj48vvsnvhiwa
16 Sep 22
Regulation FD Disclosure
4:09pm
8-K
EX-99.1
knpefp8lukz0 lh
15 Aug 22
Regulation FD Disclosure
5:12pm